

Advancements in Ocular Regenerative Therapies

Wojciech Tomczak, Weronika Winkler-Lach, Martyna Tomczyk-Socha and Marta Misiuk-Hojło

Table S1. Summary of the nine clinical trials in retinal diseases.

Title	NCT number	Status	Design	Brief description	Age/group demographics	Conditions
Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II	NCT03011541	Recruiting	<ul style="list-style-type: none">Intervention Model: Single Group AssignmentIntervention Model Description: Single Arm- Arm 1. Comparator is natural history of the disease.Masking: None (Open Label)Primary Purpose: Treatment	Evaluating the use of autologous bone marrow-derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease	18 years and older	<ul style="list-style-type: none">Retinal DiseaseAge-Related Macular DegenerationRetinitis PigmentosaStargardt DiseaseOptic NeuropathyNonarteritic Ischemic Optic NeuropathyOptic AtrophyOptic Nerve DiseaseGlaucomaLeber Hereditary Optic NeuropathyBlindnessVision Loss NightVision Loss PartialVision, LowRetinopathyMaculopathyMacular DegenerationRetina Atrophy
			<ul style="list-style-type: none">MultinationalMulticentre	A follow-up study of patients transplanted in the HOLOCORE clinical trial who consent to participate.	Adults and children	<ul style="list-style-type: none">Limbal Stem Cell Deficiency Due to Ocular Burn

Patients With LSCD Due to Ocular Burns			<ul style="list-style-type: none"> Time perspective: Prospective Primary Purpose: to collect long-term efficacy and safety data 				
Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency	NCT03949881	Recruiting	<ul style="list-style-type: none"> Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment 	A clinical trial performed to evaluate tolerance and efficacy of the autologous jugal mucosa cell sheet cultured using innovative process.	18 years and older	•	Total Bilateral Limbal Cell Deficiency
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study	NCT03981549	Active, not recruiting	<ul style="list-style-type: none"> Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment 	To evaluate whether intravitreal autologous CD34+ stem cell therapy is safe, feasible and potentially beneficial in eyes with vision loss from central retinal vein occlusion (CRVO).	18 years and older	•	Central Retinal Vein Occlusion
The Effects of Allogeneic Simple Limbal Epithelial Transplantation	NCT04021134	Recruiting	<ul style="list-style-type: none"> Observational Model: Case-Only Time Perspective: Prospective Primary Purpose: assessing the SLET effectiveness 	To investigate the effect of allogeneic SLET and re-epithelialization after allogeneic SLET.	10 to 90 years old	•	Limbal Stem-cell Deficiency
Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells	NCT05705024	Not yet recruiting	<ul style="list-style-type: none"> Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Care Provider) Primary Purpose: Treatment 	The assessment of efficacy of locally delivered allogenic mesenchymal stromal cells on chronic epitheliopathies.	18 years and older	•	Corneal Ulcer

Treatment With Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Aqueous Deficient Dry Eye Disease	NCT03878628	Active, not recruiting	<ul style="list-style-type: none"> Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment 	To assess the safety and feasibility of allogeneic adipose tissue-derived mesenchymal stem cells injected into the lacrimal gland in patients with Aqueous Deficient Dry Eye Disease.	18 years and older	<ul style="list-style-type: none"> Dry Eye Kerato Conjunctivitis Sicca Aqueous Tear Deficiency
Ocular Graft-Versus-Host-Disease After Allogeneic Haematopoietic Stem Cell Transplantation	NCT05170347	Recruiting	<ul style="list-style-type: none"> Observational Model: Cohort Time Perspective: Prospective Primary Purpose: to collect data and expand knowledge 	Ocular GVHD occurs in 30-70% of patients after HSCT. oGVHD can severely impact patients' quality of life. This study aims to understand the population-based epidemiology of oGVHD and long-term ophthalmic outcomes.	18 years and older	<ul style="list-style-type: none"> Graft Vs Host Disease Haematological Malignancy Cancer
A Safety Surveillance Study in Subjects with Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy	NCT03167203	Enrolling by invitation	<ul style="list-style-type: none"> Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment 	To evaluate late-onset adverse events in AIRM-sponsored clinical trial participants who underwent sub-retinal transplants of human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells.	18 years and older	<ul style="list-style-type: none"> Macular Degenerative Disease